Results 221 to 230 of about 220,523 (312)

Foxs1-mediated transformation of CD34⁺ fibroblast to myCAFs promotes tumor growth. [PDF]

EMBO Mol Med
Yang J, Chen T, Zhang R, Xu J, Zhao X, Yang M, Chen Z, Sun S, Chen X, Zhang S, Jiang L, Zheng Y, Hu Y, Xu Q, Lin W, Shen L, Zhang L.   +16 more
europepmc   +1 more source

Long non‐coding RNAs at the crossroads of inflammation, cancer and angiogenesis: Molecular mechanisms and their potential as therapeutic targets

British Journal of Pharmacology, EarlyView.
Long non‐coding RNAs (lncRNAs), a broad class of non‐protein‐coding RNAs, are characterized as new regulators of gene expression at the epigenetic, transcriptional, and post‐transcriptional level. Thus, lncRNAs are involved in the regulation of physiological processes and the development of human diseases and cancer by modulating proinflammatory ...
Charlie Leboff, Pamela Calle‐Mendoza, Maria Hatziapostolou, Christos Polytarchou   +3 more
wiley   +1 more source

Identification of elements determining <i>KIR</i> gene demethylation at the CD56-bright stage of NK cell development. [PDF]

iScience
Li H, Koenigs NT, Ruesch M, Troy E, Brancato-Buentello O, Sun Z, Wu X, Chen X, Zhao Y, Freud AG, Anderson SK.   +10 more
europepmc   +1 more source

Deep intronic ANK1 variants causing pseudo‐exon inclusion in hereditary spherocytosis: Whole‐genome sequencing and functional assessment

British Journal of Haematology, EarlyView.
Victor Marin, Alexandre Janin, Céline Renoux, Yoann Huguenin, AURAGEN consortium, Stéphanie Dulucq, Louis Lebreton, Philippe Joly, Julian Boutin   +8 more
wiley   +1 more source

Histone deacetylase inhibitors as venetoclax‐sensitising partners in acute myeloid leukaemia: Mechanisms, pharmacology and translational perspectives

British Journal of Pharmacology, EarlyView.
Abstract Venetoclax combined with hypomethylating agents has improved treatment for older or unfit patients with acute myeloid leukaemia (AML), but resistance and relapse remain common. This review analyses the rationale for combining venetoclax with inhibitors of histone deacetylase (HDAC).
Jaebok Lee, Marc Diederich
wiley   +1 more source

An acquired case of plaque-like CD34-positive dermal fibroma. [PDF]

JAAD Case Rep
Glennon C, Vazquez MR, Cerda-Smith C, Stamey C, Selim MA, Fresco A, Kroshinsky D.   +6 more
europepmc   +1 more source

MEN1 Deficiency Drives Lung Cancer Progression via Activation of MMP10‐Mediated Angiogenesis

Cancer Science, EarlyView.
MEN1 deficiency promotes JunD‐mediated upregulation of MMP10 expression, which cleaves pro‐HB‐EGF and activates endothelial EGFR. This triggers the PI3K/Akt and MEK/ERK signaling pathways, thereby driving angiogenesis and tumor progression. MMP10 inhibitor treatment blocks this cleavage, suppresses EGFR signaling, and thereby delays malignant ...
Chengyu Wei, Xiangyu Liu, Shimin Hu, Xiaodie Shen, Yingli Liu, Xinxin Qin, Ye Zhou, Jianqi Zheng, Bingke Tian, Jingfang Hong, Yongxia Song, Di Wang, Linlin Peng, Jinxia Ding, Fang Wang, Hui Zhang, Shihao Zhang, Huan Qiu   +17 more
wiley   +1 more source

RUNX1+23 enhancer marks erythro-megakaryocyte lineages in early waves of hematopoiesis in human ESC differentiation. [PDF]

Blood Adv
Nishida C, Kobayashi M, Syed A, Kramer P, Cheng H, Wenzel PL, Osato M, Chobirko JD, Grimson A, Slukvin II, Davis BR, Yoshimoto M.   +11 more
europepmc   +1 more source

Flow cytometric identification of plasmacytoid dendritic cells in acute myeloid leukaemia: Challenges and practical considerations

British Journal of Haematology, EarlyView.
Mariana S. Vieira, Pietro B. Belmonte, Natália A. Marcondes, Raquel Q. Vidal, Flavo B. Fernandes, Liane N. Rotta   +5 more
wiley   +1 more source

Quizartinib Resistance Mutations and Treatment Outcomes in Relapsed or Refractory FLT3‐ITD–Positive AML

Cancer Science, EarlyView.
ABSTRACT Quizartinib is a FMS‐like tyrosine kinase 3 (FLT3) inhibitor indicated for FLT3 internal tandem duplication (FLT3‐ITD)–positive acute myeloid leukemia (AML). We aimed to evaluate quizartinib resistance mechanisms, in addition to efficacy and safety outcomes, in patients with relapsed or refractory FLT3‐ITD–positive AML.
Yuichiro Semba, Toshihiro Miyamoto, Senji Kasahara, Yoshikane Kikushige, Takahiro Maeda, Goichi Yoshimoto, Shuichi Ota, Akio Saito, Yuho Najima, Hiroki Hosoi, Daigo Niiya, Koji Kato, Koji Nagafuji, Takashi Akasaka, Tomohiko Kamimura, Atsushi Takita, Maiko Narahara, Tadashi Toki, Koichi Iwanaga, Koji Yonemoto, Mine Harada, Koichi Akashi   +21 more
wiley   +1 more source